GSK delivers strong 2023 performance and upgrades growth outlooks

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Overig advies 02/02/2024 13:33
Broad-based performance drives sales, profits and earnings growth:
Total 2023 sales £30.3 billion +5% and +14% ex COVID
Vaccines sales +25%, +24% ex COVID. Shingrix £3.4 billion +17%, Arexvy £1.2 billion
Specialty Medicines sales -8%, +15% ex COVID with HIV +13%; General Medicines sales +5%
Total operating profit and Total continuing EPS for 2023 reflects strong growth, with lower charges for contingent consideration liabilities remeasurement
Adjusted operating profit +12% (with further positive impact of +4% ex COVID) and Adjusted EPS +16% (with further positive impact of +6% ex COVID). This reflected strong sales ex COVID and higher royalty income, partly offset by increased investment in R&D and new product launches

2023 Q4 2023
£m %AER %CER £m %AER %CER
Turnover 30,328 3 5 8,052 9 15
Turnover ex COVID 30,134 12 14 8,032 12 17
Total operating profit 6,745 5 10 573 (69) (60)
Total continuing EPS 121.6p 10 16 8.6p (77) (68)
Adjusted operating profit 8,786 8 12 1,752 10 21
Adjusted operating margin % 29.0% 1.2ppts 1.8ppts 21.8% 0.1ppts 1.2ppts
Adjusted EPS 155.1p 11 16 28.9p 12 25
Cash generated from operations 8,096 2 3,681 75
Organic R&D delivery and targeted business development supports future growth:
71 Vaccines and Specialty Medicines now in clinical development, including 18 in phase III/registration
Strong pipeline progress, with 4 major product approvals: Arexvy RSV vaccine; Apretude for HIV prevention; Ojjaara for myelofibrosis and Jemperli in 1L endometrial cancer
Targeted business development further strengthens the pipeline including: acquisition of Bellus Health and proposed acquisition of Aiolos Bio (Respiratory), licence agreements with Janssen (Infectious Diseases) and Hansoh Pharma (Oncology)
Significant late-stage R&D milestones expected in 2024, including: approval of Arexvy in 50-59 year-olds; regulatory submission for meningitis (ABCWY) vaccine; phase III data for depemokimab (severe asthma), Nucala (COPD), gepotidacin (UTIs/gonorrhoea), Jemperli (endometrial cancer)
2024 guidance and 2023/2024 dividends:
Expect 2024 turnover growth of between 5 to 7%; Adjusted operating growth of between 7 to 10%; Adjusted EPS growth of between 6 to 9%
Increased dividend of 16p declared for Q4 2023; 58p FY 2023; 60p expected for 2024
Upgrade to longer-term outlooks:
2021-2026 outlook increased to sales more than +7% CAGR and Adjusted operating profit more than +11% CAGR
2031 sales outlook increased to more than £38 billion; Adjusted operating margins broadly stable through dolutegravir patent loss of exclusivity

see &

Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord

Copyrights © 2000 by all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.